The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the pharma company continues to expand its capabilities in artificial ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s ...

Starting from the antibody sequence ... In January 2025, Alchemab announced an agreement with Eli Lilly and Company. Under the terms of the agreement, Alchemab will collaborate with Lilly to ...